HIF1A and non-small cell lung carcinoma: Hypoxia is a key concern during the treatment of non-small cell lung cancer (NSCLC) [39], as with pulmonary metastasis of OSCC, and hypoxia-inducible factor 1 alpha (HIF-1α) has been associated with increased tumor resistance to therapeutic agents such as cisplatin.